Article info
Sjögren’s syndrome
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
- Correspondence to Dr Stephen John Oliver, Translational Medicine, Novartis Pharma, Basel 4002, Switzerland; stephen.oliver{at}novartis.com
Citation
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Publication history
- Received November 10, 2018
- Revised January 21, 2019
- Accepted February 14, 2019
- First published March 2, 2019.
Online issue publication
April 12, 2019
Article Versions
- Previous version (2 March 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.